Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Multiple sclerosis: Page 2
Agilent launches liquid chromatography-mass spectrometry system in U.S.
Agilent's K6460S Clinical Edition triple quadrupole (TQ) LC-MS system is a U.S. Food and Drug Administration (FDA) class I device. It features a preset liquid chromatograph and mass spectrometer, as well as the clinical edition of the company's MassHunter software, according to the firm.
March 29, 2020
Thermo Fisher, NanoPin partner on infectious disease workflows
The partnership will utilize Thermo Fisher's LC-MS technology and NanoPin's diagnostic platform to identify disease-related antigens from patient blood samples, Thermo Fisher said.
February 13, 2020
Lineagen reports high accuracy for fragile X genetic test
The Salt Lake City-based company specializes in genetic testing for autism spectrum disorder and other conditions associated with developmental delays.
October 28, 2019
T2 Biosystems wins Medicare payment approval
As of October 1, 2019, U.S. hospitals treating Medicare inpatients with sepsis will now be eligible for a maximum NTAP amount of $97.50 -- 65% of the list price for one test -- for the T2Bacteria panel in addition to the appropriate sepsis diagnosis-related group (MS-DRG) reimbursement that hospitals receive under the Medicare hospital inpatient prospective payment system (IPPS), according to T2. The T2Bacteria panel is designed to detect sepsis-causing bacterial pathogens in the bloodstream in three to five hours without a blood culture.
August 6, 2019
MedTest Dx to launch new Clinitox line at AACC 2019
Targeted at labs that perform confirmation testing, the new Clinitox Calibrators and Controls line is designed to eliminate the need to acquire and set up materials, perform multiple handling and measuring steps, and manage controls and certifications.
July 31, 2019
Quanterix boosts NfL assays with UmanDiagnostics acquisition
In a statement about the deal, Quanterix said the acquisition secures the supply of highly specific NfL antibodies for use in its Simoa NfL assays and services and should accelerate the availability of diagnostics.
June 26, 2019
Most Popular
Labcorp to pay $19M to settle kickback, false claims lawsuit
Vaccine effectiveness against Omicron variants may change over time
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment
Deepcell releases single-cell morphology data sets at AGBT general meeting
Siemens Healthineers, Unilabs ink 200-million euro agreement
Previous Page
Page 2 of 2